technology license agreements

Royalty Report: Drugs, Biotechnology, Medical – Collection: 47832

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4

Category:

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Biotechnology
  • Medical
  • Supply
  • Therapeutic
  • Stem cells
  • Immune
  • cell therapy
  • Diagnostic
  • Cancer
  • HIV / AIDs

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 47832

License Grant
The Licensor, a Spanish public institution dedicated to research, grants Spanish Licensee an exclusive license of all rights it has to the PATENT, in accordance with the terms set forth in this Agreement.
License Property
The European patent is number EP05077186.4, Cell Populations having Immunoregulatory Activity, Method for Isolation and Uses. Subsequently, the Licensee has applied for several extensions of such application (PCT, Canada, Mexico, Singapore, USA, China, Japan, Israel, South Korea, Australia, India and EP2), hereinafter, all of them jointly referred to as the patent.

The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (IFN-?) by expressing indolamine-2,3-dioxygenase (IDO) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subjects immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues.

IPSCIO Record ID: 47933

License Grant
The Spanish University patent families referred to as PCX006 and PCX007 are the subject of a co ownership agreement with the Spanish Licensee. Under the terms of this agreement, the University assigned all exploitation rights, including the right to license or sub-license to third parties.
License Property
University signed an agreement for the Assignment of the Rights to Exploit Spanish invention patents no. 200402355, entitled “IDENTIFICATION AND ISOLATION OF MULTIPOTENT CELLS FROM NON-OSTEOCHONDRAL MESENCHYMAL TISSUE”, and no. 200402083, entitled “Biomaterial for suture”

PCX006 is a patent family claiming a non osteochondral derived multipotent adult stem cell population characterized by a set of biological markers.
PCX007 is a patent family claiming an adipose derived stem cell composition characterized by a panel of cell surface markers, methods of preparation of such a composition and adipose tissue derived stromal stem cells in treating fistula and wounds.

(WO2006037649/11/167,061) IDENTIFICATION AND INSOLATION OF MULTIPOTENT CELLS FROM NON-OSTEOCHONDRAL MESENCHYMAL TISSUE
The present invention relates to isolated multipotent adult cells which are isolated from non-osteochondral mesenchymal tissue and are characterized by the presence and absence of a set of cell surface markers. The invention also relates to a method for identifying and isolating a population of said cells, as well as to the applications thereof, for example, in the manufacture of a pharmaceutical composition for the repair and regeneration of tissues.

Field of Use
The Licensee is an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from our proprietary technology platforms of allogeneic, or donor-derived, stem cells.

IPSCIO Record ID: 7597

License Grant
Therefore the Licensor, a University, grants an exclusive license to the Licensed Patents, and an exclusive license to the Know How, to make, have made, use, import, offer to sell and sell Licensed Products and to practice the Licensed Process(es) in the Field of Use and Territory to the Licensee
Licensee may sublicense the rights granted.
License Property
The invention relates to methods for modulating the immune function through targeting of CLIP molecules.

Invention Disclosures
CU1760C- Selective Modulation of Gamma Delta T Cells to Treat Autoimmune Diseases, HIV, and Cancer
CU1969C – Competitive inhibitors of Invariant Chain expression and/or ectopic CLIP binding
CU1971C- Use of soluble H-2M (HLA-DM) as a CLIP displacement therapy (combined with CU1969C and patents filed under CU1969C)
CU2131C- Topical HIV prevention cream/gel (provisional application was abandoned as it was covered under applications filed in CU1760C and CU1969C)
CU2253C – The use of non-specific CLIP displacing peptides to treat or prevent chronic disease mediated by infectious organisms (no patents filed yet)
CU2254C – The use of peptides derived from an infectious organism that displace CLIP in order to treat or prevent chronic conditions mediated by those very organisms (no patents filed yet)

Patent Applications
Country
Serial No
File Date
Title
lnternal ID

United States
60/886,852
01/26/2007
Methods of Modulating Immune Function Through Targeting of Invariant Chain/CD74 and Clip
CU1760C- PPA1

United States
60/906,731
03/13/2007
Immune Mechanism For The Depletion of CD4+ T Cells
CU1760H- PPA2

PCT
PCT/US2008/001097
01/28/2008
Methods of Modulating Immune Function
CU1760C- PCT1

United States
12/011,643
01/28/2008
Methods of Modulating Immune Function
CU1760C-US2

United States
12/021'118
01/28/2008
Methods of Modulating Immune Function
CU1760C-US1

United States
61/191,740
09/11/2008
The Immune Response to HIV
CU1760C- PPA3

Country
Serial No
File Date
Title
lnternal ID

United States
61/000,152
10/23/2007
Competitive Inhibitors of Invariant Chain Expression and/or Ectopic Clip Binding
CU1969C- PPA1

United States
61/135,942
07/25/2008
Clip Inhibitors and Methods of Modulating Immune Function
CU1969C- PPA2

United States
61/135,964
07/25/2008
Competitive Inhibitors of Invariant Chain Expression and/or Ectopic Clip Binding
CU1996C- PPA3

United States
61/137,150
07/25/2008
Methods for Treating Viral Disorders
CU1969C-PPA4

PCT
PCT/US2008/012078
10/23/2008
Competitive Inhibitors of Invariant Chain Expression and/or Ectopic Clip Binding
CU1969C-PCT1

United States
15/508,554
07/23/2009
Methods for Treating Viral Disorders
CU1969C- US1

PCT
Pending
7/23/2009
Methods For Treating Viral Disorders
CU1969C-PCT3

PCT
Pending
7/23/2009
Clip Inhibitors and Methods of Modulating Immune Function
CU1969C-PCT2

United States
12/508,543
7/23/2009
Clip Inhibitors and Methods of Modulating Immune Function
CU1969C-US2

United States
61/135,922
7/25/2008
Proteins for Use in Diagnosing and Treating Infection and Disease
CU2421H-PPA1

United States
12/508,532
7/23/2009
Proteins for Use in Diagnosing and Treating Infection and Disease
CU2421H-US1

PCT
Unknown
7/23/2009
Proteins for Use in Diagnosing and Treating Infection and Disease
CU2421H-PCT1

Field of Use
Field of Use means the diagnosis, detection, prevention, and treatment of any disease.

IPSCIO Record ID: 47833

License Grant
Two Spanish Licensors, including a University, have an exclusive license agreement with a Spanish Licensee of all rights to the Patent.
License Property
The agreement is for a patent under number PCT/IB2009/006597 entitled Uses of Mesenchymal Stem Cells. Licensee has the intention of applying for future international extensions of such application, hereinafter, all of them jointly referred to as the Patent.
Field of Use
Systemic inflammatory response syndrome (SIRS) is an inflammatory state of the whole body without a specific source of infection. It can be caused by many factors, including but not limited to trauma, surgery, adrenal insufficiency, pulmonary embolism, myocardial infarction, hemorrhage, anaphylaxis, drug overdose, immunodeficiency and burns. There are four major diagnostic symptoms of SIRS, as listed below, but the presence of any two of these is sufficient for a diagnosis.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.

Related Content

  1. technology license agreements Royalty Report: Drugs, Drug Discovery, Therapeutic – Collection: 248009
  2. technology license agreements Royalty Report: Drugs, Therapeutic, Disease – Collection: 248094
  3. technology license agreements Royalty Report: Drugs, Proteins, Antibody – Collection: 315803

Related products

  • technology license agreements
    Add to cart

    Royalty Report: Drugs, Cancer, Disease – Collection: 26159

    $100.00
  • technology license agreements
    Add to cart

    Royalty Report: Drugs, Diagnostic, Biotechnology – Collection: 3402

    $100.00
  • technology license agreements
    Add to cart

    Royalty Report: Electrical & Electronics – Collection: 26328

    $100.00
  • technology license agreements
    Add to cart

    Royalty Report: Drugs, Biotechnology, Agriculture Forestry & Fishing – Collection: 3850

    $100.00